{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T18:41:17Z","timestamp":1789065677180,"version":"build-2803163510"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40265-024-02075-8","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T09:02:28Z","timestamp":1723021348000},"page":"1143-1148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Elafibranor: First Approval"],"prefix":"10.1007","volume":"84","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"issue":"9","key":"2075_CR1","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1056\/NEJMe2313802","volume":"390","author":"B Schnabl","year":"2024","unstructured":"Schnabl B. PPAR agonists in primary biliary cholangitis. N Engl J Med. 2024;390(9):855\u20138.","journal-title":"N Engl J Med"},{"issue":"3","key":"2075_CR2","first-page":"736","volume":"11","author":"H You","year":"2023","unstructured":"You H, Duan W, Li S, et al. Guidelines on the diagnosis and management of primary biliary cholangitis (2021). J Clin Transl Hepatol. 2023;11(3):736\u201346.","journal-title":"J Clin Transl Hepatol"},{"key":"2075_CR3","unstructured":"Genfit. FDA and EMA grant Genfit\u2019s elafibranor orphan drug designation for primary biliary cholangitis (PBC) [media release]. 29 Jul 2019. http:\/\/www.genfit.com."},{"key":"2075_CR4","unstructured":"Genfit. Genfit announces FDA grant of breakthrough therapy designation to elafibranor for the treatment of PBC [media release]. 18 Apr 2019. http:\/\/www.genfit.com."},{"key":"2075_CR5","unstructured":"Genfit. Genfit upates 2024 outlook following acceptance of elafibranor filings in primary biliary cholangitis (PBC) [media release]. 8 Dec 2023. http:\/\/www.genfit.com."},{"key":"2075_CR6","unstructured":"Ipsen Biopharmaceuticals Inc. IQIRVO (elafibranor) tablets, for oral use: US prescribing information. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218860s000lbl.pdf. Accessed 4 Jul 2024."},{"key":"2075_CR7","unstructured":"Ipsen Pharma. Ipsen\u2019s Iqirvo\u00ae receives US FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis [media release]. 10 Jun 2024. https:\/\/www.ipsen.com\/press-releases\/ipsens-iqirvo-receives-u-s-fda-accelerated-approval-as-a-first-in-class-ppar-treatment-for-primary-biliary-cholangitis\/."},{"key":"2075_CR8","unstructured":"European Medicines Agency. CHMP summary of positive opinion for Iqirvo (elafibranor). 2024. https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-iqirvo_en.pdf. Accessed 29 Jul 2024."},{"key":"2075_CR9","unstructured":"Terns P. Terns Pharmaceuticals announces exclusive licensing and collaboration agreement with Genfit to develop and commercialize elafibranor in the Greater China region [media release]. 24 Jun 2019. http:\/\/www.ternspharma.com."},{"key":"2075_CR10","unstructured":"Genfit. Genfit and Terns Pharmaceuticals Announce $228MM strategic partnership to develop and commercialize elafibranor in Greater China [media release]. 24 Jun 2019. http:\/\/www.genfit.com."},{"key":"2075_CR11","unstructured":"Ipsen, Genfit. Ipsen and Genfit enter into exclusive licensing agreement for elafibranor, a phase III asset evaluated in primary biliary cholangitis, as part of a long-term global partnership [media release]. 17 Dec 2021. http:\/\/www.ipsen.com."},{"issue":"6","key":"2075_CR12","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jhep.2021.01.013","volume":"74","author":"JM Schattenberg","year":"2021","unstructured":"Schattenberg JM, Pares A, Kowdley KV, et al. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J Hepatol. 2021;74(6):1344\u201354.","journal-title":"J Hepatol"},{"issue":"9","key":"2075_CR13","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2306185","volume":"390","author":"KV Kowdley","year":"2023","unstructured":"Kowdley KV, Bowlus CL, Levy C, et al. Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med. 2023;390(9):795\u2013805.","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1007\/s40265-024-02088-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02075-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02075-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02075-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T08:34:50Z","timestamp":1727512490000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02075-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":13,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["2075"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02075-8","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-024-02088-3","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"22 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-024-02088-3","URL":"https:\/\/doi.org\/10.1007\/s40265-024-02088-3","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Hannah Blair is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}